Table 1.

CA inhibitory agents evaluated for combination cancer treatment, their Ki values against therapeutically relevant enzyme isoforms and general information on the current status.

Drug/Drug Candidate	Chemical Structure	Ki (nM)		Current Status	Ref
Acetazolamide (AZ)		CA I	250	systemic CAI clinically used to treat glaucoma, edema, certain types of epilepsy	[13,14]
		CA II	12
		CA IX	25
		CA XII	5.7
Methazolamide		CA I	50	systemic CAI clinically used to treat glaucoma	[13,14]
		CA II	14
		CA IX	27
		CA XII	3.4
SLC-0111		CA I	5080	in clinical trials as adjuvant agent in advanced solid tumorsPhase Ib/II	[15]
		CA II	960
		CA IX	45
		CA XII	4.5
n-Octyl sulfamate		CA I	378	rarely used tool compound for in vitro experiments	[16]
		CA II	15
		CA IX	4
		CA XII	-
S4		CA I	5600	in preclinical studies	[17]
		CA II	546
		CA IX	7
		CA XII	2
FC-531A		CA I	1230	in preclinical studies	[17]
		CA II	450
		CA IX	6
		CA XII	4